Navigation Links
A Majority of Surveyed PCPs and Endocrinologists Indicate that they will Prescribe Contrave, Lorqess and Qnexa if these Therapies are Approved for Obesity

BURLINGTON, Mass., Nov. 4, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed primary care physicians (PCPs) and endocrinologists indicate that—if these therapies are approved for obesity—they will prescribe Orexigen Therapeutics/Takeda's Contrave (a fixed dose combination of naltrexone and bupropion), Arena Pharmaceuticals/Eisai's Lorqess (lorcaserin) and Vivus's Qnexa (a fixed dose combination of phentermine and topiramate).

The new U.S. Physician & Payer Forum report entitled Contrave, Lorqess, and Qnexa; How Will Physician and Payer Attitudes Shape the Market for These Emerging Obesity Therapies? finds that surveyed PCPs are less likely than endocrinologists to prescribe Contrave or Lorqess but over 75 percent of both physician groups intend to prescribe Qnexa if approved. Additionally, there is little difference between the likelihood of endocrinologists to prescribe any of these three novel therapies, as approximately three quarters indicate that they intend to prescribe each of these agents for obesity.

"The obesity drug market is at an unprecedented inflection point as Contrave, Lorqess and Qnexa are attempting to enter an underserved market that is characterized by a rapidly growing patient population and very high unmet need," said Decision Resources Analyst Matthew Scutcher, Ph.D. "Meanwhile, there have been several major market challenges in recent years including the failure of Sanofi-Aventis's Acomplia (rimonabant) to gain regulatory approval in the United States and the withdrawal of Abbott's Meridia. Additionally, GlaxoSmithKline's Alli—an over-the-counter formulation of orlistat (Roche's Xenical)—has failed to bring new life to the obesity market."

The report also finds that 13 percent of surveyed clinicians and 23 percent of surveyed managed care organization's (MCO) pharmacy directors are aware of agents other than Eli Lilly/Amylin's Byetta (exenatide), Novo Nordisk's Victoza (liraglutide) and Amylin's Symlin (pramlintide) as being prescribed off-label for the treatment of weight loss. Other off-label weight loss drugs identified by clinicians and MCO pharmacy directors include topiramate (Ortho-McNeil's Topamax, generics), bupropion (GlaxoSmithKline's Wellbutrin, generics) and metformin.    

The report is based on a U.S. survey of 75 PCPs, 75 endocrinologists and 30 MCO pharmacy directors.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources, Inc.

Christopher Comfort


SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aspirin Named 8th World Wonder by Majority of Americans
2. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
3. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
4. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
5. Volcano Expands Access to FFR with Ability to Integrate with the Majority of Hemodynamic Monitoring Systems
6. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
7. Martek Biosciences Announces Agreement to Sell Majority of Winchester, Ky. Manufacturing Site
8. Survey Reveals Majority of Americans Hold onto Myths About What Causes Colds and How to Treat Them
9. MultiCells Majority Owned Subsidiary Acquires Bioabsorbable Interventional Cardiology Stent Assets
10. Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
11. Nycomed to Accelerate Expansion in China Through Acquisition of Majority Stake in Guangdong Techpool Bio-Pharma
Post Your Comments:
(Date:11/30/2015)... , November 30, 2015 North America ... is expected to grow at a CAGR of 7.6% from 2015 ... valued at USD 135.6 million in 2014, and is expected to ... --> According to the new Market Research Report "North America ... By End User (Hospitals, ambulatory care, others) - Analysis And Forecast ...
(Date:11/30/2015)... , November 30, 2015 /PRNewswire/ ... --> adds a ... for 2010 - 2015 with comprehensive ... a range of deal types, such ... strategic alliances. ...
(Date:11/30/2015)... Nov. 30, 2015  Kevin Smith has been ... a global pioneer in wireless monitoring of vital ... MA , Mr. Smith will be responsible ... commercial strategy.  He will also directly oversee partnering ... clinical evidence for SensiumVitals, the first early warning ...
Breaking Medicine Technology:
(Date:11/30/2015)... DE (PRWEB) , ... November 30, 2015 , ... ... guest lecturer at a University of Delaware Accounting and Management of Information Systems ... software solutions for mid-market businesses. Sommer will speak at before student in the ...
(Date:11/30/2015)... ... November 30, 2015 , ... Cycling, running, and walking are regular Sunday activities ... morning of February 28, 2016. , That’s when the 7th annual ANF Group ... to help children and families at Joe DiMaggio Children’s Hospital. , The ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced that the ... ointment to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s ... the comparison chart and ingredient list allows our customers to quickly see why, ...
(Date:11/30/2015)... ... , ... At Grand Dental PC, their priority is to deliver quality care ... problems, you need to turn to a dentist who listens and responds; an experienced ... friendly dentist who counsels you on the best ways to maintain and improve your ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... Dr. Seth ... three office locations, patients can visit Dr. Margulies to experience the best available orthodontic ... hold the title of "NJ Top Dentist"! , Orthodontics is the branch of dentistry ...
Breaking Medicine News(10 mins):